Skip to main content

Table 3 Histopathological and molecular subtypes of the patients enrolled in the study

From: Quantitative mathematical objective evaluation of contrast-enhanced spectral mammogram in the assessment of response to neoadjuvant chemotherapy and prediction of residual disease in breast cancer

Histological Subtype:
 • Invasive ductal carcinomas (IDC).
 • Invasive lobular carcinomas (ILC).
 • Mixed invasive ductal and lobular carcinomas.
 • Invasive tubular carcinoma (ITC).
Number and percentage
• 36/42 tumors (85.7%)
• 4/42 tumors (9.5%)
• 1/42 tumor (2.4%)
• 1/42 tumor (2.4%)
Biomarker s status of the tumors:
HER2 over-enriched cancers.
HER2-negative/HR–positive cancer
Triple-negative cancers.
Luminal A cancer.
Number and percentage
9/42 were (21.4 %)
17/42 (40.45%)
12 /42 (28.6%)
4/42 (9.5 %)